Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomized, Blinded, Placebo-controlled Phase I Clinical Trial to Evaluate the Safety, Tolerability, and Immunogenicity of SARS-CoV-2 Bivalent mRNA Vaccine (LVRNA021) in Participants Aged 18 Years and Older Who Have Received SARS-CoV-2 Vaccine

NCT05939596 is registered in ClinicalTrials.gov with AIM Vaccine Co., Ltd. as lead sponsor.

NCT NCT05939596
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05939596 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomized, Blinded, Placebo-controlled Phase I Clinical Trial to Evaluate the Safety, Tolerability, and Immunogenicity of SARS-CoV-2 Bivalent mRNA Vaccine (LVRNA021) in Participants Aged 18 Years and Older Who Have Received SARS-CoV-2 Vaccine
Lead sponsor
AIM Vaccine Co., Ltd.
Phase
Phase 1
Overall status
Unknown status
Start date
August 10, 2023
Completion date
August 25, 2024
Enrollment
60 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

sars-cov-2